Women’s perspective of botulinum toxin treatment for overactive bladder symptoms
Tóm tắt
This study aimed to evaluate the women’s’ views and expectations about outcomes and complications of botulinum toxin treatment for overactive bladder (OAB) symptoms. Consecutive women with OAB symptoms and detrusor overactivity were requested to fill out a multiple choice questionnaire to assess whether they would consider botulinum and what outcomes as well as complications they would find acceptable to undergo this treatment. Two hundred sixty-one women, mean age of 58 (range, 38–78) years, were studied. Two hundred twenty-four were treatment-naive women (group A), while 37 were no responders to anticholinergics (group B). Only 49.6% of women in group A and 54% in group B would accept botulinum toxin. No significant differences were found between treatment-naive women and non-responders to anticholinergics (p > 0.05). Acceptance of botulinum toxin treatment involves a complex interaction of efficacy and possible complications. The balance of these factors changes the acceptability of the treatment.
Tài liệu tham khảo
Abrams P, Cardozo L, Fall M et al (2002) The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn 21:167–178
Stewart WF, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327–336
Abrams P (2000) Introduction: overactive bladder and its treatments. Urology 55:1–2
Stewart WF, Corey R, Herzog AR et al (2001) Prevalence of overactive bladder in women: results from the NOBLE program. Int Urogynaecol J 12:S66
Srikrishna S, Robinson D, Cardozo L, Vella M (2007) Management of overactive bladder syndrome. Postgrad Med J 83(981):481–486
Andersson K-E (1988) Current concepts in the treatment of disorders of micturition. Drugs 35:477–494
Payne CK, Kelleher C (2007) Redefining response in overactive bladder syndrome. BJU Int 99(1):101–106
Salvatore S, Khullar V, Cardozo L et al (2005) Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity. Eur J Obstet Gynecol Reprod Biol 119:237–241
Kelleher CJ, Cardozo LD, Khullar V et al (1997) A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 104:988–993
Rapp DE, Lucioni A, Katz EE et al (2004) Use of botulinum toxin A for the treatment of refractory overactive bladder symtptoms: an initial experience. Urolog 63:1071–1075
Kuo HC (2004) Urodynamic evidence of effectiveness of botulinum A toxin injection in the treatment of detrusor overactivity refractory to anticholinergic agents. Urology 63:868–872
Chancellor MB, O’Leary M, Erickson J (2003) Successful use of bladder botulinum toxin injection to treat refractory overactive bladder. J Urol 169(suppl):351
Abrams P, Andersson KE, Birder L et al (2009) Proceedings of the 4th International consultation on incontinence. Recommendations of the international scientific committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence. In: Abrams P, Cardozo L, Khouri S, Wein A (eds) Incontinence. Plymouth, UK, pp 1767–1798
Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164:692–697
Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB (2004) Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology 64:871–875
Apostolidis A, Popat R, Yiangou Y et al (2005) Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 174:977–982
Schmid DM, Sauermann P, Werner M et al (2006) Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 176(1):177–185
Patel AK, Patterson JM, Chapple CR (2006) Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: a critical analysis of results. Eur Urol 50:684–709
Sahai A, Dowson C, Khan MS, Dasgupta P (2008) Re: efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int 101(4):515–516
Jeffery S, Fynes M, Lee F, Wang K, Williams L, Morley R (2007) Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int 100(6):1302–1306
Kuo HC (2007) Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol 178:1359–1363
Mattiasson A, Djurhuus JC, Fonda D, Lose G, Nordling J, Stohrer M (1998) Standardisation of outcome studies in patients with lower urinary tract dysfunction: a report on general principles from the standardisation committee of the International Continence Society. Neurourol Urodyn 17:249–253
Blaivis JG, Appell RA, Fantl JA et al (1997) Standards of efficacy for evaluation of treatment outcomes in urinary incontinence: recommendations of the urodynamic society. Neurourol Urodyn 16:145–147
Blaivas JG (1998) Outcome measures for urinary incontinence. Urology 51:11–19
Scientific Committee of the First Consultation on Incontinence (2000) Assessment and treatment of urinary incontinence. Lancet 355:2153–2158
Apostolidis A, Dasgupta P, Denys P et al (2009) Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 55(1):100–119